Clear All
785 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
C9307 Linvoseltamab-gcpt Lynozyfic 1mg Immunotherapy Monoclonal Antibody BCMA, CD3 No 2025 Jan 12, 2026 Mar 18, 2026 In Use
J9184 Gemcitabine (avyxa) Avgemsi 200mg Chemotherapy Antimetabolite Pyrimidine Analog No 2025 Jan 12, 2026 In Use
Q5162 Denosumab-nxxp Bildyos/Bilprevda 1mg Immunotherapy Monoclonal Antibody RANKL No 2026 Mar 18, 2026 In Use
J9277 Pembrolizumab and berahyaluronidase alfa-pmph KEYTRUDA QLEX 1mg Immunotherapy Checkpoint Inhibitor PD-1 No 2025 Mar 18, 2026 In Use
J9278 Carboplatin (avyxa) Kyxata 1mg Chemotherapy Alkylating Agent Platinum Compound No 2025 Mar 18, 2026 In Use
J9183 Gemcitabine intravesical Inlexzo 225mg Chemotherapy Antimetabolite Pyrimidine Analog No 2025 Mar 18, 2026 In Use
J9003 Leuprolide Camcevi etm 1mg Hormonal Therapy GnRH Agonist No 2022 Mar 18, 2026 In Use
J8502 Aprepitant Aponvie 1mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 No 2023 Mar 18, 2026 In Use
J9601 Linvoseltamab-gcpt Lynozyfic 1mg Immunotherapy Monoclonal Antibody BCMA, CD3 No 2025 Mar 18, 2026 In Use
Q5161 Denosumab-kyqq Ankelso/Bosaya 1mg Immunotherapy Monoclonal Antibody RANKL No 2025 Mar 18, 2026 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.